Compare CPHI & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPHI | MDAI |
|---|---|---|
| Founded | N/A | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.5M | 53.8M |
| IPO Year | 2008 | 2021 |
| Metric | CPHI | MDAI |
|---|---|---|
| Price | $0.98 | $1.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 1.0M | 180.4K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.88 |
| EPS | ★ N/A | N/A |
| Revenue | $4,144,268.00 | ★ $19,650,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $23.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.38 | $1.18 |
| 52 Week High | $19.19 | $2.97 |
| Indicator | CPHI | MDAI |
|---|---|---|
| Relative Strength Index (RSI) | 46.90 | 44.53 |
| Support Level | $0.54 | $1.49 |
| Resistance Level | $1.43 | $1.77 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 5.01 | 30.91 |
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
Spectral AI Inc is an AI company focused on predictive medical diagnostics. Its DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound's capacity to heal or not-heal by a specified time point in the future. The company focuses on the burn indication which is supported by the BARDA PBS contract.